{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T14:51:36Z","timestamp":1648997496476},"reference-count":82,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>W\u00e4hrend Parkinson mit seiner vielf\u00e4ltigen und sehr individuellen Kombination aus motorischen und nichtmotorischen Symptomen zunehmend genauer charakterisiert ist, nicht zuletzt durch die Untersuchung von gro\u00dfen Patientenkohorten mit Deep-Phenotyping-Approach, folgt die Therapie weiterhin einem einheitlichen Schema. Durch bessere Stratifikation bieten Pr\u00e4zisionsmedizin-Ans\u00e4tze die M\u00f6glichkeit, die Behandlung und patientenzentrierte Versorgung zu verbessern. Spezifische Therapien f\u00fcr den Einsatz bei monogenetischen Parkinson-Formen, die aktuell untersucht werden, k\u00f6nnten helfen, Krankheitsmechanismen zu verstehen und dadurch auch zum Verst\u00e4ndnis des idiopathischen Parkinson-Syndroms beitragen, sowie neue Behandlungsziele aufzeigen. Wir zeigen Daten zur Vorhersage von Wirksamkeit und Langzeit-Vorteil von aktuellen medikament\u00f6sen Behandlungen sowie von Tiefer Hirnstimulation (THS) im Kontext von wachsendem pharmakogenetischen Wissen. Konfrontiert mit asymptomatischen Tr\u00e4gern genetischer Mutationen (monogenetische Erkrankung) von variabler Penetranz und prodromalen Stadien wie REM-Schlaf-Verhaltensst\u00f6rungen, zeichnen sich erste pr\u00e4ventive Therapiestrategien ab. Ihr Einfluss auf die Krankheitsprogression und Aussichten f\u00fcr die klinische Praxis m\u00fcssen adressiert werden.<\/jats:p>","DOI":"10.1055\/a-1149-2204","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T22:47:31Z","timestamp":1591138051000},"page":"558-566","source":"Crossref","is-referenced-by-count":0,"title":["Ans\u00e4tze zur Etablierung von Pr\u00e4zisionsmedizin bei der Parkinson-Krankheit mit dem Schwerpunkt Genetik"],"prefix":"10.1055","volume":"88","author":[{"given":"Lara","family":"Stute","sequence":"additional","affiliation":[{"name":"Parkinson Research Clinic, Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg"},{"name":"Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Sur-Alzette, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rejko","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"Parkinson Research Clinic, Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg"},{"name":"Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Sur-Alzette, Luxembourg"},{"name":"Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s40273-018-0686-6","article-title":"The future of precision medicine: potential impacts for health technology assessment","volume":"36","author":"J Love-Koh","year":"2018","journal-title":"Pharmacoeconomics."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/pme-2018-0036","volume":"15","author":"C Le Tourneau","year":"2018","journal-title":"Per Med"},{"key":"ref3","first-page":"34","article-title":"Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols : A review and examples","author":"LA Renfro","year":"2017","journal-title":"Special Article"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/ane.12694","article-title":"Parkinson\u2019s disease in Germany: Prevalence and incidence based on health claims data","volume":"136","author":"M Nerius","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"17","author":"E Ray Dorsey","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mds.26657","article-title":"Motor subtype in Parkinson\u2019s disease: different disorders or different stages of disease?","volume":"31","author":"JG Nutt","year":"2016","journal-title":"Mov Disord"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/brain\/awp234","article-title":"A clinico-pathological study of subtypes in Parkinson\u2019s disease","volume":"132","author":"M Selikhova","year":"2009","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0000000000002461","article-title":"Age at onset and Parkinson disease phenotype","volume":"86","author":"G Pagano","year":"2016","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1474-4422(06)70411-2","article-title":"Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism","volume":"5","author":"A Schrag","year":"2006","journal-title":"Lancet Neurol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/mds.20213","article-title":"Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations","volume":"19","author":"CG Goetz","year":"2004","journal-title":"Mov Disord"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00415-012-6624-1","article-title":"Expanded and independent validation of the movement disorder society-unified Parkinson\u2019s disease rating scale (MDS-UPDRS)","volume":"260","author":"P Martinez-Martin","year":"2013","journal-title":"J Neurol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.parkreldis.2014.12.031","article-title":"The burden of non-motor symptoms in Parkinson\u2019s disease using a self-completed non-motor questionnaire: A simple grading system","volume":"21","author":"KR Chaudhuri","year":"2015","journal-title":"Park Relat Disord"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"109641","DOI":"10.1016\/j.pnpbp.2019.109641","article-title":"Clinimetric approach to rating scales for the assessment of apathy in Parkinson\u2019s disease: a systematic review","volume":"94","author":"D Carrozzino","year":"2019","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","article-title":"Non motor subtypes and Parkinson\u2019s disease","volume":"22","author":"A Sauerbier","year":"2016","journal-title":"Park Relat Disord"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jns.2018.03.024","article-title":"Intercepting Parkinson disease non-motor subtypes: a proof-of-principle study in a clinical setting","volume":"388","author":"ME Di Battista","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref21","first-page":"1","article-title":"Parkinson\u2019s disease subtypes identified from cluster analysis of motor and non-motor symptoms","volume":"9","author":"J Mu","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"ref22","first-page":"1","article-title":"Recent advances in biomarkers for Parkinson\u2019s disease","volume":"10","author":"R He","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1474-4422(17)30122-9","article-title":"Prediction of cognition in Parkinson\u2019s disease with a clinical\u2013genetic score: A longitudinal analysis of nine cohorts","volume":"16","author":"G Liu","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.parkreldis.2018.10.025","article-title":"New era in disease modification in Parkinson\u2019s disease: review of genetically targeted therapeutics","volume":"59","author":"SP Sardi","year":"2019","journal-title":"Park Relat Disord"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JPD-171100","article-title":"Global, yet incomplete overview of Cohort studies in Parkinson\u2019s disease","volume":"7","author":"S Heinzel","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"29","author":"T Pringsheim","year":"2014","journal-title":"Mov Disord"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.04.005","article-title":"Converging environmental and genetic pathways in the pathogenesis of Parkinson\u2019s disease","volume":"306","author":"LF Burbulla","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.nbd.2018.11.012","article-title":"The role of monogenic genes in idiopathic Parkinson\u2019s disease","volume":"124","author":"X Reed","year":"2019","journal-title":"Neurobiol Dis"},{"key":"ref30","first-page":"1","article-title":"The genetic architecture of Parkinson\u2019s disease","volume":"4422","author":"C Blauwendraat","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1093\/brain\/awz191","article-title":"Genetic analysis of Mendelian mutations in a large UK population-based Parkinson\u2019s disease study","volume":"142","author":"MMX Tan","year":"2019","journal-title":"Brain"},{"issue":"06","key":"ref32","first-page":"568","article-title":"LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. Neurology","volume":"83","author":"F Hentati","year":"2014"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"247.e9-247.e13","DOI":"10.1016\/j.neurobiolaging.2017.05.009","article-title":"NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases","volume":"57","author":"C Blauwendraat","year":"2017","journal-title":"Neurobiol Aging"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2017.06.005","article-title":"10 years of GWAS discovery: biology, function, and translation","volume":"101","author":"PM Visscher","year":"2017","journal-title":"Am J Hum Genet"},{"key":"ref35","first-page":"2","article-title":"Genes in familial parkinsonism and their role in sporadic Parkinson\u2019s disease","volume":"251","author":"R Kr\u00fcger","year":"2004","journal-title":"J Neurol Suppl"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/IJHTS.S8681","article-title":"In: Drug discovery in Parkinson\u2019s disease: update and developments in the use of cellular models","volume":"2011","author":"S Finkbeiner","year":"2011","journal-title":"Int J High Throughput Screen"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S1353-8020(11)70022-0","article-title":"Role of mendelian genes in \u201esporadic\u201c Parkinson\u2019s disease","volume":"18","author":"S Lesage","year":"2012","journal-title":"Park Relat Disord"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/mds.25600","article-title":"Population-specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson\u2019s disease (GEO-PD) consortium","volume":"28","author":"MG Heckman","year":"2013","journal-title":"Mov Disord"},{"key":"ref39","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-444-63233-3.00014-2","volume-title":"Genetics of Parkinson disease","author":"A Domingo","year":"2018"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1474-4422(11)70175-2","article-title":"Association of LRRK2 exonic variants with susceptibility to Parkinson\u2019s disease: a case\u2013control study","volume":"10","author":"OA Ross","year":"2011","journal-title":"Lancet Neurol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2016.00071","article-title":"A personalized approach to Parkinson\u2019s disease patients based on founder mutation analysis","volume":"7","author":"N Giladi","year":"2016","journal-title":"Front Neurol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study","volume":"7","author":"DG Healy","year":"2008","journal-title":"Lancet Neurol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"568 LP","DOI":"10.1212\/WNL.0000000000000675","article-title":"LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance","volume":"83","author":"F Hentati","year":"2014","journal-title":"Neurology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1741-7015-6-33","article-title":"LRRK2 in Parkinson\u2019s disease \u2013 Drawing the curtain of penetrance: A commentary","volume":"6","author":"R Kr\u00fcger","year":"2008","journal-title":"BMC Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1021\/acsinfecdis.9b00051","volume":"5","author":"S Herbst","year":"2019","journal-title":"ACS Infect Dis"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41575-018-0006-9","volume":"15","author":"P Derkinderen","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/hmg\/ddi439","article-title":"The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity","volume":"15","author":"CJ Gloeckner","year":"2006","journal-title":"Hum Mol Genet"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.27414","article-title":"Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic","volume":"33","author":"SP Sardi","year":"2018","journal-title":"Mov Disord"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.stem.2013.01.008","article-title":"Genetic correction of a lrrk2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression","volume":"12","author":"P Reinhardt","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/mds.27699","volume":"34","author":"N Br\u00fcggemann","year":"2019","journal-title":"Mov Disord"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/mds.27558","article-title":"Understanding the role of genetic variability in LRRK2 in Indian population","volume":"34","author":"A Kishore","year":"2019","journal-title":"Mov Disord"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","article-title":"Gaucher disease epidemiology and natural history: a comprehensive review of the literature","volume":"22","author":"L Nalysnyk","year":"2017","journal-title":"Hematology"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"E Sidransky","year":"2009","journal-title":"N Engl J Med"},{"key":"ref55","first-page":"1","article-title":"Glucocerebrosidase and its relevance to Parkinson disease","volume":"14","author":"J Do","year":"2019","journal-title":"Mol Neurodegener"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"GBA-associated Parkinson\u2019s disease: reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"K Brockmann","year":"2015","journal-title":"Mov Disord"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mdc3.12000","article-title":"Advances in the genetics of Parkinson\u2019s disease: a guide for the clinician","volume":"1","author":"UM Sheerin","year":"2014","journal-title":"Mov Disord Clin Pract"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/brain\/awx285","article-title":"Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease","volume":"140","author":"LA Robak","year":"2017","journal-title":"Brain"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.ymgme.2018.12.298","article-title":"Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation","volume":"126","author":"M Judith Peterschmitt","year":"2019","journal-title":"Mol Genet Metab"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"GHB Maegawa","year":"2009","journal-title":"J Biol Chem"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"A McNeill","year":"2014","journal-title":"Brain"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of \u03b2-glucocerebrosidase reduces pathological \u03b1-synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons","volume":"36","author":"JR Mazzulli","year":"2016","journal-title":"J Neurosci"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the Treatment of Patients with Parkinson Disease with and without Glucocerebrosidase Gene Mutations: a Nonrandomized, Noncontrolled Trial","volume":"77","author":"S Mullin","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.stem.2008.09.015","article-title":"Extreme makeover: converting one cell into another","volume":"3","author":"Q Zhou","year":"2008","journal-title":"Cell Stem Cell"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.drudis.2016.05.005","article-title":"High-throughput platforms for the screening of new therapeutic targets for neurodegenerative diseases","volume":"21","author":"DN Rocha","year":"2016","journal-title":"Drug Discov Today"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3748\/wjg.v20.i13.3534","volume":"20","author":"G Stocco","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","article-title":"Pharmacogenomics","volume":"394","author":"DM Roden","year":"2019","journal-title":"Lancet"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.bmcl.2017.07.075","article-title":"Current approaches to the treatment of Parkinson\u2019s disease","volume":"27","author":"JM Ellis","year":"2017","journal-title":"Bioorganic Med Chem Lett"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/mdc3.12444","article-title":"Pharmacogenetics of Parkinson\u2019s disease in clinical practice","volume":"4","author":"JC Corvol","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/brain\/aww109","article-title":"Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study","volume":"139","author":"M Masellis","year":"2016","journal-title":"Brain"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/mds.22218","article-title":"A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson\u2019s disease (the ADAGIO study): rationale, design, and baseline characteristics","volume":"23","author":"CW Olanow","year":"2008","journal-title":"Mov Disord"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-017-8473-7","article-title":"Genetics and Treatment Response in Parkinson\u2019s Disease: an Update on Pharmacogenetic Studies","volume":"20","author":"C Politi","year":"2018","journal-title":"NeuroMolecular Med"},{"key":"ref76","first-page":"18: 815\u2013821","article-title":"The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson\u2019s disease, levodopa treatment response, and complications","author":"M Bialecka","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"ref77","first-page":"0","article-title":"Deep brain stimulation for monogenic Parkinson\u2019s disease: a systematic review","volume":"0","author":"T Kuusim\u00e4ki","year":"2019","journal-title":"J Neurol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1007\/s00415-012-6469-7","article-title":"Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson\u2019s disease","volume":"259","author":"D Weiss","year":"2012","journal-title":"J Neurol"},{"key":"ref79","first-page":"1","article-title":"Deep brain stimulation and genetic variability in Parkinson\u2019s disease: a review of the literature","volume":"5","author":"J Ligaard","year":"2019","journal-title":"Npj Park Dis"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2016.01.005","article-title":"Outcome of deep brain stimulation in slowly progressive multiple system atrophy: a clinico-pathological series and review of the literature","volume":"24","author":"WG Meissner","year":"2016","journal-title":"Park Relat Disord"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.brs.2018.02.015","article-title":"Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson\u2019s disease","volume":"11","author":"HS Dafsari","year":"2018","journal-title":"Brain Stimul"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1093\/brain\/awz285","article-title":"Non-motor outcomes depend on location of neurostimulation in Parkinson\u2019s disease","volume":"142","author":"JN Petry-Schmelzer","year":"2019","journal-title":"Brain"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","article-title":"The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies","volume":"43","author":"A Galbiati","year":"2019","journal-title":"Sleep Med Rev"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10072-016-2744-1","article-title":"Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson\u2019s disease: a meta and meta-regression analysis","volume":"38","author":"X Zhang","year":"2017","journal-title":"Neurol Sci"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/brain\/awz030","article-title":"Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study","volume":"142","author":"RB Postuma","year":"2019","journal-title":"Brain"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.26898","article-title":"PREDICT-PD: an online approach to prospectively identify risk indicators of Parkinson\u2019s disease","volume":"32","author":"AJ Noyce","year":"2017","journal-title":"Mov Disord"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson\u2019s disease","volume":"30","author":"D Berg","year":"2015","journal-title":"Mov Disord"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/mds.27670","article-title":"Prodromal Parkinson\u2019s disease: the decade past, the decade to come","volume":"34","author":"RB Postuma","year":"2019","journal-title":"Mov Disord"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4338\/ACI-2016-02-RA-0028","article-title":"Electronic data collection in epidemiological research: The use of REDCap in the pelotas birth cohorts","volume":"7","author":"C Blumenberg","year":"2016","journal-title":"Appl Clin Inform"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"RM Califf","year":"2018","journal-title":"Exp Biol Med"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"L Parnetti","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/omi.2017.0181","article-title":"From genomics to omics landscapes of Parkinson\u2019s disease: revealing the molecular mechanisms","volume":"22","author":"S Reden\u0161ek","year":"2018","journal-title":"Omi A J Integr Biol"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1149-2204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T22:42:08Z","timestamp":1600728128000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1149-2204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":82,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2020,9,21]]},"published-print":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1149-2204","relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}